Login / Signup

An update on novel pharmacological agents for primary sclerosing cholangitis.

Camilla GalloBright Oworae HowardsonLaura CristoferiMarco CarboneM Eric GershwinInvernizzi Pietro
Published in: Expert opinion on therapeutic targets (2022)
The heterogeneity and poor prevalence of PSC, its uncertain pathophysiology, and the lack of surrogate endpoints are the major challenges in drug discovery. Strategies that synergistically target microbiota, bile acids, and liver fibrosis are needed. In parallel, we must enhance biomarkers discovery to develop surrogate endpoints, as biochemical markers' fluctuations over the time hamper their effectiveness. Magnetic resonance cholangiopancreatography tools that accurately measure bile duct changes represent a potential marker for disease monitoring. A collaboration between academia, research consortia, patient's associations, and industry is required.
Keyphrases